# Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

> **NCT03681561** · PHASE1,PHASE2 · RECRUITING · sponsor: **Veronika Bachanova** · enrollment: 54 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03681561
- **Lead sponsor:** Veronika Bachanova
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-09-13
- **Primary completion:** 2026-03
- **Final completion:** 2027-07
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03681561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03681561, "Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03681561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*